2 results

• Abbott Pulls Bioresorbable Vascular Scaffold From European Market As FDA Investigates Blood Clot Risks

  April 10, 2017

  Irvin Jackson

  Abbott Laboratories is pulling its BVS dissolving stent from markets in Europe, but leaving them for sale in the U.S., as concerns grow over blood clots and heart attacks linked to the devices.

• FDA Investigates Abbott Absorb GT1 Bioresorbable Vascular Scaffold (BVS) Over Heart Problems

  March 20, 2017

  Irvin Jackson

  The FDA is warning about a risk of heart problems, such as heart attacks and deaths, associated with Abbott's BVS dissolving heart implant.